Latest News

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interch...

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangea

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574)...

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Anti

Teva Reports Growth in Fourth Quarter and Full Year 2023

Teva Reports Growth in Fourth Quarter and Full Year 2023

Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy

Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024...

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Fina

Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic A...

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibo

New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults wi...

New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Mi

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatme...

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference

Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business